MINNEAPOLIS, MN / ACCESSWIRE / July 6, 2017 / PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company
focused on commercialization of innovative medical devices and therapeutics continues to receive recognition for its novel
orthopedic devices. PetVivo's Chief Technical Officer David B. Masters, Ph.D. has received the Star Abstract Award from the
Orthopedics Biomaterials Special Interest Group, Society for Biomaterials. The award, which acknowledges significant advances in
the field, recognizes abstracts that have an average abstract review score greater than or equal to 4.0 on a 1-5 scale.
Dr. Masters' oral presentation of the award abstract is titled "Particles for Osteoarthritis Treatment: Injected Wet Particulate
of Collagen-Elastin-Glycosaminoglycan Matrix into Synovial Fluid Mechanically Cushion Joint with Long Duration."
"It is an honor to be recognized by scientists in your field of study," noted Dr. David Masters. "Leading biomaterial experts
are increasingly recognizing the importance of incorporating natural biochemical components into their studied polymer biomaterials
to help promote natural regeneration of tissue. We have been fortunate to be early adopters in utilizing collagen and its
elastin-carbohydrate tissue counterparts to formulate a strong natural biomaterial matrix, allowing our company to carve out
significant intellectual property around protein based device configurations that naturally help the body heal and protect
itself."
Dr. Masters also concludes: "Our MasterGel Hydrophilic Biomaterial (MHB) particles provide safe cushioning and lubricity to the
joint, as well as a scaffolding that can help natural healing processes rebuild functional tissue. In this way, MHB particles
alleviate the pain associated with missing and damaged cartilage to provide a protective environment in much the same way native
cartilage protects the joint. Our MHB scaffolding imparts a chemical-structural feedback for natural cell-mediated responses, which
allows implanted grafts and devices to integrate and/or regenerate endogenous tissues."
"For example, our biomaterial has been used in a number of tissue applications, including spinal disks, tissue glue, cosmetic
dermal filler for skin wrinkle repair (clinicaltrials.gov NCT00414544), urinary sphincter muscle regeneration, blood vessel grafts
and more, including over $5 million in National Institutes of Health funding. Indeed, we show that the current treatment for canine
osteoarthritis, which relies on constant NSAID medication, can be eliminated for about a year following a single injection of MHB
particles." Dr. Masters' complete abstract can be found here.
The MHB Particles are used in the production of PetVivo's lead product, Kush™ Canine for the treatment of canine osteoarthritis.
Kush Canine is scheduled for commercial launch later this year, followed shortly thereafter by Kush Equine for the treatment of
lameness in horses. The particles used to make the Kush devices are part of a large pipeline of patented animal and human
therapeutics developed and manufactured by Gel-Del® Technologies.
You can learn more about Kush Canine and PetVivo by visiting the company's website at www.petvivo.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTC PINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization
of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device
industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the
accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently
regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion
animal market. The company's product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents
protects the company's products, production processes, and biomaterials. PetVivo's lead product, a veterinarian-administered joint
injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in
large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
PetVivo Holdings, Inc. routinely posts periodic reports and press releases that include important information on our corporate
website and/or Facebook page. Therefore, for more information please see us on Facebook and visit our website at
www.petvivo.com.
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties
and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue
reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after
the date of these forward-looking statements.
CONTACT:
John Lai
PetVivo Holdings, Inc.
Email: info@petvivo.com
Phone: 612-296-7305
SOURCE: PetVivo Holdings Inc.
